Literature DB >> 12170567

The use of methadone for cancer pain.

Carla Ripamonti1, Mauro Bianchi.   

Abstract

Methadone is not a new analgesic drug [69]. Several studies have demonstrated that methadone is a valid alternative to morphine, hydromorphone, and fentanyl for the treatment of cancer-related pain, and extensive reviews on the subject have been published in recent years [10,23,25,64,70,71]. Most people involved in pain therapy, however, are not well informed about the properties of methadone. The authors believe that the low cost of methadone paradoxically contributes to the limited knowledge of its characteristics and to the restricted therapeutic use of this drug. The low cost of methadone means there is little financial incentive for pharmaceutical companies to invest in research or to disseminate scientific information. Unfortunately, the lack of scientific information from pharmaceutical companies frequently results in a lack of knowledge on the part of physicians. Unless the existing approach changes, both culturally and politically, ignorance about methadone will persist among medical experts. The low cost of methadone, rather than being an advantage, will result in the limited exploitation of an effective drug.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12170567     DOI: 10.1016/s0889-8588(02)00017-5

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN: 0889-8588            Impact factor:   3.722


  11 in total

1.  Methadone use in children and young adults at a cancer center: a retrospective study.

Authors:  Doralina L Anghelescu; Lane G Faughnan; Gisele M Hankins; Deborah A Ward; Linda L Oakes
Journal:  J Opioid Manag       Date:  2011 Sep-Oct

Review 2.  Methadone for treatment of cancer pain.

Authors:  John Bryson; Anoo Tamber; Dori Seccareccia; Camilla Zimmermann
Journal:  Curr Oncol Rep       Date:  2006-07       Impact factor: 5.075

3.  The role of methadone in cancer-induced bone pain: a retrospective cohort study.

Authors:  Merlina Sulistio; Robert Wojnar; Seraphina Key; Justin Kwok; Ziad Al-Rubaie; Natasha Michael
Journal:  Support Care Cancer       Date:  2020-07-06       Impact factor: 3.603

Review 4.  Methadone: applied pharmacology and use as adjunctive treatment in chronic pain.

Authors:  R Brown; C Kraus; M Fleming; S Reddy
Journal:  Postgrad Med J       Date:  2004-11       Impact factor: 2.401

5.  The effect of quinidine, used as a probe for the involvement of P-glycoprotein, on the intestinal absorption and pharmacodynamics of methadone.

Authors:  Evan D Kharasch; Christine Hoffer; Dale Whittington
Journal:  Br J Clin Pharmacol       Date:  2004-05       Impact factor: 4.335

6.  Bioavailabilities of rectal and oral methadone in healthy subjects.

Authors:  Ola Dale; Pamela Sheffels; Evan D Kharasch
Journal:  Br J Clin Pharmacol       Date:  2004-08       Impact factor: 4.335

7.  The role of methadone in opioid rotation-a Polish experience.

Authors:  Wojciech Leppert
Journal:  Support Care Cancer       Date:  2008-11-29       Impact factor: 3.603

8.  Mechanism of autoinduction of methadone N-demethylation in human hepatocytes.

Authors:  Scott D Campbell; Amanda Crafford; Brian L Williamson; Evan D Kharasch
Journal:  Anesth Analg       Date:  2013-06-03       Impact factor: 5.108

9.  Three patients and their drugs: A parallel case paper on paediatric opiate use and withdrawal.

Authors:  Harold B Siden; Kathleen Collin
Journal:  Paediatr Child Health       Date:  2005-03       Impact factor: 2.253

10.  Pharmacists leadership in a medication shortage response: Illustrative examples from a health system response to the COVID-19 crisis.

Authors:  Mahmoud A Ammar; Lydia J Tran; Bryan McGill; Abdalla A Ammar; Phu Huynh; Nilesh Amin; Michael Guerra; Ginger E Rouse; Diana Lemieux; Dayna McManus; Jeffrey E Topal; Matthew W Davis; LeeAnn Miller; Marina Yazdi; Molly Billstein Leber; Rebecca A Pulk
Journal:  J Am Coll Clin Pharm       Date:  2021-04-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.